A Randomised, Parallel Arm, Open-Label Trial Comparing Degarelix With Goserelin Plus Anti-Androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-High Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)

Trial Profile

A Randomised, Parallel Arm, Open-Label Trial Comparing Degarelix With Goserelin Plus Anti-Androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-High Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Degarelix (Primary) ; Bicalutamide; Goserelin
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Jun 2014 Pooled analysis results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 15 Apr 2014 Results from a pooled analysis presented at the 29th Congress of the European Association of Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top